Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRS-100
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
CRS-100 (formerly ANZ-100) is a live-attenuated strain of the bacterium *Listeria monocytogenes* (Lm) developed as a cancer immunotherapy. It is engineered using the LADD (Live, Attenuated, Double-Deleted) platform, which involves the deletion of the *actA* and *inlB* genes to significantly reduce virulence by preventing cell-to-cell spread and limiting the infection of hepatocytes. Despite these attenuations, the bacterium remains capable of being phagocytosed by antigen-presenting cells (APCs), where it escapes the phagosome and enters the cytosol. This process triggers potent innate immune signaling pathways, including the activation of Toll-like receptors (TLRs) and the STING pathway, which promotes the maturation of dendritic cells and the subsequent activation of tumor-specific CD4+ and CD8+ T-cell responses. CRS-100 was primarily investigated in Phase 1 clinical trials for the treatment of advanced carcinomas with liver metastases, serving as a foundational vector for subsequent antigen-specific Listeria-based vaccines.
- Brand names
- ANZ-100ANZ100ANZ 100
- Other names
- Live-attenuated Listeria monocytogenes
02
Targets
STING (Stimulator of interferon genes protein)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR2 (Toll-like Receptor 2)TLR5
Beyond the preview
Go deeper on CRS-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRS-100.